| Literature DB >> 31994774 |
Rachael A Lawson1,2, Sarah J Richardson1,2, Alison J Yarnall1,2,3, David J Burn4, Louise M Allan1,5.
Abstract
INTRODUCTION: People with Parkinson disease (PD) may be at increased risk of delirium and associated adverse outcomes. Delirium is an acute neuropsychiatric syndrome defined by confusion and inattention and is common in older adults. Previous studies may have underestimated the prevalence of delirium in PD because of overlapping symptoms, lack of awareness, and poorly defined criteria. We aimed to identify the prevalence and incidence of delirium in inpatients with PD. MEASUREMENTS: Participants were inpatients with PD admitted over a 4-month period. Delirium prevalence was classified using a standardised assessment at a single visit on the basis of the Diagnostic and Statistical Manual of Mental Disorders fifth edition (DSM-5) criteria. To capture remaining time in hospital, incident delirium was diagnosed using detailed clinical vignettes and a validated consensus method.Entities:
Keywords: Parkinson disease; delirium; incidence; inpatient; prevalence
Mesh:
Year: 2020 PMID: 31994774 PMCID: PMC7186820 DOI: 10.1002/gps.5270
Source DB: PubMed Journal: Int J Geriatr Psychiatry ISSN: 0885-6230 Impact factor: 3.485
Figure 1Flow diagram of recruitment. iPD, idiopathic Parkinson's disease
Comparison of characteristics of prevalent cases and incident cases of delirium in inpatients with PD
| Prevalent Delirium | Incident Delirium | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No Delirium, n = 35 | Prevalent Delirium, n = 18 | No Delirium, n = 23 | Incident Delirium, n = 30 | |||||||||
| Mean | SD | Mean | SD |
|
| Mean | SD | Mean | SD |
|
| |
| Age | 74.4 | 11 | 79.2 | 6.1 |
|
| 72.6 | 11.7 | 78.6 | 7.3 |
|
|
| Education, y | 12.3 | 3.3 | 12.1 | 2.7 |
| .929 | 12.6 | 3.6 | 12 | 2.6 |
| .497 |
| MDS‐UPDRS III | 49.7 | 14.7 | 56.4 | 17.7 |
| .158 | 48 | 15.1 | 55.3 | 15.3 |
| .118 |
| Hoehn and Yahr stage | 3.5 | 1 | 4.3 | 0.8 |
|
| 3.4 | 1 | 4 | 1 |
|
|
| PD duration, y | 6.3 | 4.5 | 6.8 | 4.9 |
| .612 | 6.4 | 5.1 | 6.5 | 4.3 |
| .693 |
| No. of comorbidities | 5.1 | 2.2 | 6.1 | 1.6 |
| .104 | 5.1 | 2.5 | 5.6 | 1.7 |
| .484 |
| No. of medications | 10.2 | 3.7 | 10.9 | 3.2 |
| .46 | 9.8 | 3.8 | 10.9 | 3.2 |
| .161 |
| LEDD, mg/day | 690.3 | 530.1 | 590.4 | 432.5 |
| .598 | 617.9 | 492.5 | 685.9 | 507.1 |
| .726 |
| Hospital stay duration | 6.2 | 6 | 14.7 | 15.1 |
|
| ||||||
| Clinical Frailty Scale | 5.1 | 1.4 | 6.8 | 0.5 |
|
| 4.9 | 1.4 | 6.3 | 1.1 |
|
|
| GCS total | 14.5 | 1.3 | 12.1 | 1.9 |
|
| 14.5 | 1.2 | 13 | 2.1 |
|
|
| OSLA total | 2.5 | 2.4 | 6.1 | 3.3 |
|
| 2.3 | 2.6 | 4.8 | 3.3 |
|
|
| m‐RASS | 0.2 | 0.9 | −1.1 | 2 |
|
| 0.3 | 0.8 | −0.6 | 1.8 |
| .235 |
| MDAS total | 8.7 | 3.6 | 17.7 | 5.8 |
|
| 8 | 3.6 | 14.7 | 6.2 |
|
|
Note: Significant results are highlighted in bold.
Abbreviations: GCS, Glasgow Coma Scale; LEDD, Levodopa equivalent daily dose; MDAS, Memorial Delirium Assessment Scale; MDS‐UPDRS III, Movement Disorders Society Unified Parkinson's Disease Rating Scale Part III; MoCA, Montreal Cognitive Assessment; m‐RASS, modified Richmond Agitation and Sedation Scale; OSLA, Observational Scale of Level of Arousal; PD, Parkinson disease; PDD, Parkinson disease dementia; PD‐MCI, Mild Cognitive Impairment in Parkinson disease; SD, standard deviation.
Fisher exact test.